Diabetes

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical organizations to speak out about safety concerns.

The prevalence of obesity and diabetes has grown worldwide, presenting notable challenges to public health and health care systems.

SAN DIEGO — Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 receptor agonist experienced a decreased risk for complications but an increased risk for mortality.

Intentional weight loss of 5% or more, coupled with reduced waist circumference was associated with lower risk for death from cancer, CVD or any cause among postmenopausal women followed for more than 18 years, data show.

SAN DIEGO — GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to results presented here.

Hormonal changes can cause physiological and pathological changes in the eye, and eye care providers should monitor pregnant patients well past delivery, according to a literature review published in Clinical and Experimental Optometry.

Diabetes mortality declined in the U.S. by 32.1% from 2000 to 2019, with decreases in mortality observed among all racial and ethnic groups and in most U.S. counties, researchers reported in Diabetes Care.

Slightly elevated blood glucose within a range of what is generally considered “normal” may be associated with increased risk for heart disease, researchers reported.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes compared with dipeptidyl peptidase 4 inhibitors, results of a target trial emulation study suggested.

The increasingly popular obesity and diabetes drugs known as glucagon-like peptide-1 receptor agonists do not seem to worsen suicidality despite previous concerns, according to recent data published in BMJ.